Your browser doesn't support javascript.
loading
Risk of Cancer in Family Members of Patients with Lynch-Like Syndrome.
Picó, María Dolores; Sánchez-Heras, Ana Beatriz; Castillejo, Adela; Giner-Calabuig, Mar; Alustiza, Miren; Sánchez, Ariadna; Moreira, Leticia; Pellise, María; Castells, Antoni; Llort, Gemma; Yagüe, Carmen; Ramon Y Cajal, Teresa; Gisbert-Beamud, Alexandra; Cubiella, Joaquin; Rivas, Laura; Herraiz, Maite; Garau, Catalina; Salces, Inmaculada; Carrillo-Palau, Marta; Bujanda, Luis; López-Fernández, Adriá; Alvarez-Urturi, Cristina; López, María Jesús; Alenda, Cristina; Zapater, Pedro; Lacueva, Francisco Javier; Balaguer, Francesc; Soto, Jose-Luis; Murcia, Óscar; Jover, Rodrigo.
Afiliação
  • Picó MD; Servicio de Medicina Digestiva, Hospital General Universitario de Elche, Elche, 03203 Alicante, Spain.
  • Sánchez-Heras AB; Servicio de Oncología Médica, Hospital General Universitario de Elche, Elche, 03203 Alicante, Spain.
  • Castillejo A; Unidad de Genética Molecular, Hospital General Universitario de Elche, 03203 Alicante, Spain.
  • Giner-Calabuig M; Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, 03010 Alicante, Spain.
  • Alustiza M; Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, 03010 Alicante, Spain.
  • Sánchez A; Servicio de Medicina Digestiva, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd. University of Barcelona, 08036 Barcelona, Spain.
  • Moreira L; Servicio de Medicina Digestiva, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd. University of Barcelona, 08036 Barcelona, Spain.
  • Pellise M; Servicio de Medicina Digestiva, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd. University of Barcelona, 08036 Barcelona, Spain.
  • Castells A; Servicio de Medicina Digestiva, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd. University of Barcelona, 08036 Barcelona, Spain.
  • Llort G; Servicio de Oncología Médica, Hospital Universitari Parc Taulí, Sabadell, Consorci Sanitari de Terrassa, Terrassa, 08208 Barcelona, Spain.
  • Yagüe C; Servicio de Oncología Médica, Hospital Universitari Parc Taulí, Sabadell, Consorci Sanitari de Terrassa, Terrassa, 08208 Barcelona, Spain.
  • Ramon Y Cajal T; Servicio de Medicina Digestiva, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Gisbert-Beamud A; Servicio de Medicina Digestiva, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Cubiella J; Servicio de Medicina Digestiva, Complexo Hospitalario Universitario de Ourense, Instituto de Investigación Sanitaria Galicia Sur, CIBERehd, 32005 Ourense, Spain.
  • Rivas L; Servicio de Medicina Digestiva, Complexo Hospitalario Universitario de Ourense, Instituto de Investigación Sanitaria Galicia Sur, CIBERehd, 32005 Ourense, Spain.
  • Herraiz M; Servicio de Medicina Digestiva, Clínica Universidad de Navarra, 31008 Navarra, Spain.
  • Garau C; Servicio de Medicina Digestiva, Hospital de Son Llàtzer, 07198 Palma de Mallorca, Spain.
  • Salces I; Servicio de Medicina Digestiva, Hospital 12 de Octubre, 28041 Madrid, Spain.
  • Carrillo-Palau M; Servicio de Medicina Digestiva, Hospital Universitario de Canarias, 38320 Tenerife, Spain.
  • Bujanda L; Servicio de Medicina Digestiva, Hospital Donostia/Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), 20014 San Sebastián, Spain.
  • López-Fernández A; Unidad de Alto Riesgo y Prevención del Cáncer, Hospital Universitario Vall d'Hebron, 08035 Barcelona, Spain.
  • Alvarez-Urturi C; Servicio de Medicina Digestiva, Hospital del Mar, 08003 Barcelona, Spain.
  • López MJ; Servicio de Medicina Digestiva, Hospital Universitario Marqués de Valdecilla, 39008 Santandercity, Spain.
  • Alenda C; Servicio de Anatomía Patológica, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, 03010 Alicante, Spain.
  • Zapater P; Servicio de Farmacología Clínica, Hospital General Universitario de Alicante, ISABIAL, CIBERehd, IDiBE, UMH, 03010 Alicante, Spain.
  • Lacueva FJ; Servicio de Cirugía general, Hospital General Universitario de Elche, Elche, 03203 Alicante, Spain.
  • Balaguer F; Servicio de Medicina Digestiva, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd. University of Barcelona, 08036 Barcelona, Spain.
  • Soto JL; Unidad de Genética Molecular, Hospital General Universitario de Elche, 03203 Alicante, Spain.
  • Murcia Ó; Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, 03010 Alicante, Spain.
  • Jover R; Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, 03010 Alicante, Spain.
Cancers (Basel) ; 12(8)2020 Aug 09.
Article em En | MEDLINE | ID: mdl-32784934
ABSTRACT
Lynch syndrome (LS) is a common cause of hereditary colorectal cancer (CRC). Some CRC patients develop mismatch repair deficiency without germline pathogenic mutation, known as Lynch-like syndrome (LLS). We compared the risk of CRC in first-degree relatives (FDRs) in LLS and LS patients. LLS was diagnosed when tumors showed immunohistochemical loss of MSH2, MSH6, and PMS2; or loss of MLH1 with BRAF wild type; and/or no MLH1 methylation and absence of pathogenic mutation in these genes. CRC and other LS-related neoplasms were followed in patients diagnosed with LS and LLS and among their FDRs. Standardized incidence ratios (SIRs) were calculated for CRC and other neoplasms associated with LS among FDRs of LS and LLS patients. In total, 205 LS (1205 FDRs) and 131 LLS families (698 FDRs) had complete pedigrees. FDRs of patients with LLS had a high incidence of CRC (SIR, 2.08; 95% confidence interval (CI), 1.56-2.71), which was significantly lower than that in FDRs of patients with LS (SIR, 4.25; 95% CI, 3.67-4.90; p < 0.001). The risk of developing other neoplasms associated with LS also increased among FDR of LLS patients (SIR, 2.04; 95% CI, 1.44-2.80) but was lower than that among FDR of patients with LS (SIR, 5.01, 95% CI, 4.26-5.84; p < 0.001). FDRs with LLS have an increased risk of developing CRC as well as LS-related neoplasms, although this risk is lower than that of families with LS. Thus, their management should take into account this increased risk.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article